[an error occurred while processing this directive]
中华放射肿瘤学杂志
   2025年4月7日 星期一     首 页 |  期刊介绍  |  编 委 会  |  投稿指南  |  期刊订阅  |  广告合作  |  学术影响  |  收录情况  |  联系我们  |  English
中华放射肿瘤学杂志  2022, Vol. 31 Issue (6): 539-543    DOI: 10.3760/cma.j.cn113030-20210926-00374
腹部肿瘤 最新目录| 下期目录| 过刊浏览| 高级检索 [an error occurred while processing this directive]|[an error occurred while processing this directive]
后装腔内联合组织间插植在ⅢB期宫颈癌中剂量学及疗效分析
修雨婷, 孟凡旭, 王琢, 赵康康, 王蕴龙, 陈志深, 刘敏, 田琦, 刘竣天, 孙宝胜
吉林省肿瘤医院放疗科,长春 130012
Analysis of dosimetry and clinical efficacy of intracavitary/interstitial brachytherapy in ⅢB cervical cancer
Xiu Yuting, Meng Fanxu, Wang Zhuo, Zhao Kangkang, Wang Yunlong, Chen Zhishen, Liu Min, Tian Qi, Liu Juntian, Sun Baosheng
Department of Radiotherapy, Tumor Hospital of Jilin Province, Changchun 130012, China
全文: PDF (0 KB)   HTML (1 KB) 
输出: BibTeX | EndNote (RIS)      背景资料
摘要 目的 比较基于CT图像引导下单纯后装腔内近距离治疗(ICBT)与腔内联合组织间插植治疗(IC+ISBT)两种后装方式治疗ⅢB期宫颈癌的剂量学及疗效。方法 回顾性分析2014年6月至2017年2月于吉林省肿瘤医院放疗四科治疗的宫颈癌ⅢB期患者93例的临床资料,根据近距离治疗前妇科检查和盆腔MRI检查的结果确定肿瘤残留大小和宫旁浸润情况,分为ICBT组与IC+ISBT组。比较两种后装治疗方式的D90%、D100%、V100%以及膀胱、直肠D2cm3, 观察近、远期疗效。结果 中位随访时间为60个月。所有患者5年局部控制率、无远处转移生存率、总生存率分别为83%、71%、68%。与ICBT组相比,IC+ISBT组高危临床靶体积D90%均>85Gy,两组间差异无统计学意义(P=0.188),但膀胱和直肠D2cm3剂量分别显著降低7、8Gy (P值均<0.01),且无远处转移生存率显著提高(P=0.009)。高危临床靶体积>60cm3 5年局部控制率在IC+ISBT组显著提高(P=0.029)。结论 后装腔内联合组织间插植治疗ⅢB期宫颈癌能够保证靶区覆盖的同时,显著降低远处转移发生率和危及器官受量,并显著提高大体积肿瘤的局部控制率。
服务
把本文推荐给朋友
加入我的书架
加入引用管理器
E-mail Alert
RSS
作者相关文章
修雨婷
孟凡旭
王琢
赵康康
王蕴龙
陈志深
刘敏
田琦
刘竣天
孙宝胜
关键词 宫颈肿瘤腔内联合组织间插植近距离放疗剂量学疗效    
AbstractObjective To compare the dosimetry and efficacy of intracavitary brachytherapy (ICBT) and intracavitary/interstitial brachytherapy (IC+ISBT) based on CT image guidance in the treatment of stage ⅢB cervical cancer. Methods Clinical data of 93 patients with stage ⅢB cervical cancer treated in Department of Radiotherapy of Jilin Cancer Hospital from June 2014 to February 2017 were analyzed retrospectively. According to the results ofGynecological examination and pelvic MRI before brachytherapy, confirming the size of residual tumor and the degree of parauterine infiltration, all patients were divided into the ICBT and IC+ISBT groups. The D90%, D100%, V100% and D2cm3 of bladder and rectum were compared, and the short-term and long-term efficacy was observed between two groups. Results The median follow-up time was 60 months. The 5-year local control rate, distant metastasis-free survival rate and overall survival rate of all patients were 83%, 71% and 68%, respectively. Compared with the ICBT group, HR-CTV D90% in the IC+ISBT group was all more than 85Gy, while there was no significant difference between two groups (P=0.188). The D2cm3 of bladder and rectum in the IC+ISBT group was significantly decreased by 7Gy and 8Gy (both P<0.01), and the distant metastasis-free survival rate was significantly improved (P=0.009). The 5-year local control rate in the HR-CTV volume>60cm3 in the IC+ISBT group was significantly higher than that in the IC group (P=0.029). Conclusion For patients with ⅢB cervical cancer, IC+ISBT can not only ensure target coverage, but also significantly reduce the incidence of distant metastasis and the dose of organs at risk, and significantly improve the local control rate of large tumors.
Key wordsCervical neoplasm    Intracavitary/interstitial brachytherapy    Dosimetry    Efficacy   
收稿日期: 2021-09-26     
基金资助:吉林省创新能力建设资金(2021C043-8)
通讯作者: 孙宝胜,Email:xiuyuxiong@163.com   
引用本文:   
修雨婷,孟凡旭,王琢等. 后装腔内联合组织间插植在ⅢB期宫颈癌中剂量学及疗效分析[J]. 中华放射肿瘤学杂志, 2022, 31(6): 539-543.
Xiu Yuting,Meng Fanxu,Wang Zhuo et al. Analysis of dosimetry and clinical efficacy of intracavitary/interstitial brachytherapy in ⅢB cervical cancer[J]. Chinese Journal of Radiation Oncology, 2022, 31(6): 539-543.
链接本文:  
http://journal12.magtechjournal.com/Jweb_fszlx/CN/10.3760/cma.j.cn113030-20210926-00374     或     http://journal12.magtechjournal.com/Jweb_fszlx/CN/Y2022/V31/I6/539
京公网安备11010502022167号
版权所有 © 2010《中华放射肿瘤学杂志》编辑部
地址:北京朝阳区潘学园南里17号 中国医学科学院肿瘤医院(100021)
电话:010-67700737,87788294 Email: cjron@cmaph.org
本系统由北京玛格泰克科技发展有限公司设计开发 技术支持:Support@magtech.com.cn